MedTrace Logo

Acetazolamide for Treatment Resistant Schizophrenia

NCT04887792 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-07

No results posted yet for this study

Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Conditions

Interventions

DRUG

Acetazolamide

ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.

DRUG

Placebo

Identical gelatin capsules will be prepared by filling with inert excipients.

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Vishwajit Nimgaonkar, MD PhD

    lead OTHER

Principal Investigators

  • Vishwajit L Nimgaonkar, M.D., Ph.D. · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2026-06-30
Completion
2026-12-30
FDA Drug
Yes

Countries

  • United States
  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04887792 on ClinicalTrials.gov